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INTRODUCTION
Phoshodiesterases (PDEs) form a superfamily of at least 11 intracellular iso-enzymes which are involved in the modulation of signal transduction processes via the degradation of cyclic nucleotides (cAMP and/or cGMP) (Bender and Beavo, 2006) . Type 4 cyclic nucleotide phosphodiesterases (PDE4) are a family of cAMP-specific PDEs encoded by four genes (PDE4A, PDE4B, PDE4C, and PDE4D) sharing a highly conserved catalytic domain and abundantly expressed in leukocytes (Srivani et al., 2008) . By increasing intracellular cAMP levels, PDE4 inhibitors show a broad spectrum of anti-inflammatory effects in almost all cells of the immune system. In particular PDE4 is a major player in regulating pro-inflammatory cellular functions, such as proliferation and cytokine secretion, chemotaxis, degranulation, antibody IgE release and generation of lipid mediators (Spina, 2003) . PDE4 regulates also the function of several structural cells that control lung functions such as airway smooth muscle, airway epithelium, vascular endothelium and airway sensory nerves (Fan Chung, 2006) . This, together with a large body of evidence supporting potent anti-inflammatory activity of PDE4 inhibitors in various experimental models, including models of pulmonary inflammation (Hatzelmann et al., 2010) , has generated a considerable interest in targeting PDE4 in chronic inflammatory and obstructive airway diseases (Spina, 2003) . Clinical investigations of second-generation oral PDE4 inhibitors, e.g., cilomilast, Ariflo (Barnette et al., 1998) , and roflumilast, Daxas (Hatzelmann et al., 2001) , have demonstrated efficacy in chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma (Press and Banner, 2009 ). However, the development of these compounds has been hampered by dose limiting adverse events which are mechanism-related, in particular gastrointestinal disturbances such as nausea, diarrhea, abdominal pain, vomiting and dyspepsia (Calvelry et al., 2009) 
. Roflumilast has recently been
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JPET Fast Forward. Published on January 9, 2015 as DOI: 10.1124/jpet.114.220541 at ASPET Journals on April 8, 2017 jpet.aspetjournals.org Downloaded from JPET#220541 5 approved in EU and USA for once-daily treatment of severe COPD associated with chronic bronchitis and frequent exacerbations as add-on to bronchodilator treatment. However, targetrelated gastrointestinal side effects may limit roflumilast dosage and thus optimal clinical efficacy (Giembycz, 2010; Page and Spina, 2012) . In line with this consideration, the active doses of roflumilast determined in experimental models (Martorana et al., 2005; Hatzelmann et al., 2010) hardly support the daily dose of 0.5 mg approved in COPD patients.
In the respiratory field, a logical way to improve the therapeutic index is to deliver drugs directly into the lung via the inhalation route allowing high topical efficacy coupled with low oral availability and limited systemic exposure. The PDE4 inhibitor UK-500,001 developed for inhaled administration was tested in a double-blind, placebo-controlled, 6-week trial in 209 patients with moderate-to-severe COPD but with disappointing results and the study was stopped following a planned interim analysis for futility (Vestbo et al., 2009 ). Lack of efficacy in phase II trials in asthma and COPD led to the discontinuation also of AWD 12-281 and tofimilast (Pages et al., 2009) . To date, the best in class among inhaled PDE4 inhibitors is GSK256066, which appears to be more potent than all the other PDE4 inhibitors described so far Tralau-Stewart et al., 2011) , is well tolerated in COPD patients (Watz et al., 2013) and is effective in reducing allergen challenge responses in asthma patients (Singh et al., 2010) .
In the present study we report the pharmacological characterization of (S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide (CHF6001), a novel highly potent and selective inhaled PDE4 inhibitor which was previously selected and optimized for inhaled delivery (Armani et al., 2013) . In addition to defining its profile as PDE4 inhibitor, we exensively studied anti-inflammatory activities of CHF6001 in several in vitro cellular models This article has not been copyedited and formatted. The final version may differ from this version.
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Moreover the anti-inflammatory potency and efficacy of CHF6001 was demonstrated in vivo in a rat model of endotoxin-induced acute pulmonary inflammation. Some of these data were presented in a poster form at the 2014 American Thoracic Society conference .
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Materials and Methods
Chemicals
(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide, CHF6001 (Armani et al, 2014), 6-((3-(dimethylcarbamoyl) (Hatzelmann et al., 2001) , (1s,4s)-4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexane-1-carboxylic acid, cilomilast (Pagès et al., 2009), 6-((3-(dimethylcarbamoyl) phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide, UK-500,001 (Pagès et al., 2009) , were synthesized at Chiesi Farmaceutici S.p.A., Parma, Italy. Unless otherwise stated, all other chemical reagents used in this study were purchased from Sigma-Aldrich (St. Louis, MO).
PDE4 enzymatic assays from U937 extracts. PDE4 activity was determined in U937 human monocytic supernatants cells lysate (ATCC, Manassas, USA). Cells were cultured, harvested and supernatant fraction prepared essentially as previously described (Barnette et al. 1996) . All the materials used for cell culture were from Gibco (Monza, Italy). U937 cells were grown at 37°C, 5% CO 2 in RPMI-1640 with GlutaMAX™-I medium supplemented with 10% fetal bovine serum and 100 μg/mL Pen-strep. Cells were harvested and washed twice by centrifugation (150 x g, 8 min) in cold PBS. Washed cells were resuspended in cold KrebsRinger-Henseleit buffer at a final concentration 20 x 10 6 cells /mL and sonicated. After centrifugation at 15,000 x g for 20 min, the supernatants were pooled, divided in aliquots and stored at -80°C. PDE4 activity was determined in cells supernatants by assaying cAMP This article has not been copyedited and formatted. The final version may differ from this version. inhibitor, and 0.9 mL of membrane preparation (added last). Rolipram (10 μM) was used for nonspecific binding. After 60 min incubation at 4 °C the contents of the incubation tubes were filtered through a Whatman GF/C glass filter. The membranes were washed three times with 3 mL of ice-cold buffer, and radioactivity on the separated filter disks was determined in a liquid scintillation counter. IC 50 values were determined from semilog graphs of percent inhibition versus concentration.
PDE4
Enzyme Assays. PDE4 assays were performed using recombinant PDE enzymes expressed in a baculoviral system. The radiometric assay method is a modification of the twostep method of Thompson and Appleman (1971) as described by Mackenzie et al., 2010 . All the The PDE4 inhibitors were prepared as stocks at a concentration of 40 mM in 100% DMSO and were tested at 11 concentrations (0.5% final DMSO concentration) in duplicate with a starting concentration of 1μM and a 1:10 serial dilution against human PDE4A4, PDE4B2, PDE4C2, PDE4D3. Concentration up to 5% DMSO are tolerated in this assay as reported previously (MacKenzie et al., 2010) , a notion confirmed also by a preliminary study aimed at evaluating tolerance to DMSO (estimated up to 5%).
PDEs Enzyme Assays. PDE1 was prepared from bovine brain (Gietzen, 1982) . PDE2, PDE3
and PDE5 were purified from human platelets (Schudt, 1991) . PDE6 was purified from bovine retina (Baehr W, 1979) . Recombinant human PDE7A, PDE8A1, PDE9A2, PDE10A2 and PDE11A4 were expressed in a baculovirus/ insect cell system. The radiometric assay method is a modification of the two-step method of Thompson and Appleman (1971 Human myeloid leukemia THP-1 cell line. THP-1 cell line was obtained from Sigma (St.
Louis, MO) and cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM glutamine, 100 U penicillin and 100 µg/ml streptomycin, in an atmosphere of 95% air and 5% CO 2 at 37°C. To induce differentiation into adherent macrophages, cells were plated in 48-well plates (2.5x10 5 cells/well) and incubated for 4 days (THP-1) with 50 nM of phorbol 12-myristate 13-acetate, as previously described (Daigneault et al., 2010) . supplemented with 10% FBS. Murine and rat TNFα in the supernatant were determined by quantitative ELISA kit (Bender Medsystem, Vienna, Austria) . As an indirect index of nitric oxide (NO), accumulation of nitrite in the medium production was measured by a colorimetric assay method based on the Griess reaction as previously described (Facchinetti et al., 2004) .
CD4+ T Lymphocytes. CD4+ T lymphocytes were purchased from Lonza (Base, CH). CD4+ T lymphocytes were cultured in Lymphocyte Growth Medium supplemented with 10% FBS, albumin, insulin, transferrin and gentamicin. Cells were stimulated via the T-cell receptor CD3
and CD28 co-receptor by using selective mAbs (Hatzelmann and Schudt, 2001) . For this purpose, 96-well microtiter plates were prepared on the day before cell plating: each well was incubated with 50 μ l of PBS containing 6 μ g/ml of anti-CD3 mAb (Orthoclone OKT-3; JanssenCilag, Neuss, Germany) for about 2.5 h at 37°C; plates were then stored overnight at 4°C and Neutrophil chemotaxis. Male C57BL/6J mice were bred in the animal house of the Center for Molecular Biotechnology (University of Turin, Italy) and maintained on a standard diet with tap water ad libitum and a 12:00 h light /dark cycle. Mice were sacrified by cervical dislocation. The femur and the tibia bones from both hind legs were removed and freed of soft tissue attachments, and the extreme distal tip of each extremity was cut off. Saline with 0.1% Fetal Bovine Serum was forced through the bone with a syringe. After dispersing cell clumps, the cell suspension was centrifuged (260 g, 12 min at 4°C) and resuspended in 2 ml of saline-0.1%FBS. Cells were then treated on a three-layer Percoll gradient (72%-64%-52%). Neutrophils were collected from the ring between 72%-64%, counted and concentrated at 2x10 6 cells/ml in RPMI medium. Cells were incubated with the compound at different concentration for 1h at 37°C and then let migrate against C5a 50nM for 2h in the 48 multiwell chamber. The inhibition of the compound was evaluated on the number of the cells still able to migrate towards C5a. Budesonide (1 μ mol/kg), 1 hour prior and 6 hours after LPS exposure. Dry powder formulations were prepared by blending of mainly coarse respiratory grade lactose and micronized test compound. For the challenge, rats were placed into a perspex chamber and exposed to LPS (salmonella enterica serotype) or 0.9% saline. The LPS was prepared in a solution of 0.1 mg/mL and aerosolised using a De Vibliss ultrasonic nebuliser 2000, so that 7 mL of the solution was aerosolised during a 30 min exposure period. Compressed air at 6 L min-1 was passed through the nebulizer and the output of the nebulizer was passed into the box containing the rats. 24
LPS-induced neutrophilia in rat.
hours after LPS challenge the animals were culled by an intraperitoneal injection of 1.0 mL of pentobarbitone sodium (lethobarb). The trachea was then isolated by a midline incision in the neck and separation of the muscle layers. A small incision was made into the trachea and a plastic cannula was inserted and secured in place with a suture. The airway was then lavaged using 2.5 mL of sterile PBS at room temperature. The PBS was left in the airway for 10 seconds before being removed. From this resulting lavage an aliquot (1.5 mL) was centrifuged (1200 rpm for 2 min) and 2 samples (300 μ L) of the resulting supernatant were aliquoted and stored at - 
RESULTS
CHF6001 selection
The structure of CHF6001 is shown in figure 1 . It was identified as a potent inhibitor of PDE4 activity (compound 32a) from a series of novel ester derivatives of 1-(S)-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-dichloropyridin-4-yl) ethanol (Armani et al., 2014) . In particular, esters of variously substituted benzoic acids were explored and structural modifications of the benzoic moiety were performed in order to maximize the inhibitory potency. Besides CHF6001, several other novel PDE4 inhibitors with potent antiinflammatory activity in vitro were obtained (Armani et al., 2014) .
Activity of CHF6001 and reference compounds in PDE enzyme assays
PDE4 isoenzymes exist in both LARBS and HARBS conformations. CHF6001 enzymatic activity was tested both in a LARBS conformation by utilizing an assay with PDE4 extracts from
U937 cells and in HARBS conformation by utilizing rolipram binding assay (see Materials and
Methods) in comparison with reference compounds GSK256066, roflumilast, UK 500,001 and cilomilast ( CHF6001 inhibited most of PDE4 splicing variants at sub-nanomolar concentrations (Table 2) and, similarly to GSK256066 and roflumilast, CHF6001 did not show PDE4 subtype selectivity against different PDE isoenzymes. Roflumilast is ten-fold less potent than CHF6001 with respect to PDE4 isoenzymes inhibition, apart from PDE4C, which is inhibited with a slightly lower potency. In contrast, UK 500,001 and cilomilast showed some subtype selectivity for PDE4D (Table 2) .
CHF6001 is at least 25,000 fold less potent against the following panel of PDE isoenzymes:
PDE1, PDE2, PDE3, PDE5, PDE6, PDE7A, PDE8A1, PDE9A2, PDE10A2 and PDE11A4, therefore showing a marked selectivity for PDE4 (Table 3) .
Activity of CHF6001 and reference compounds in human PBMCs, THP-1 monocytederived macrophages and CD4 + T lymphocytes
We selected two in vitro models of LPS-stimulated TNF-α to evaluate the anti-inflammatory potency of CHF6001 in comparison with other known PDE4 inhibitors, including GSK256066, which is the most potent PDE4 inhibitor so far described in the literature, UK500,001, roflumilast (the only clinically approved PDE4 inhibitor) and cilomilast. All the compounds tested inhibited TNF-α release up to a maximum of about 90% in PBMC, an outcome in line with the notion that PDE4 is the predominant isoform expressed in monocytes (Figure 2 
Activity of CHF6001 and roflumilast on neutrophilic chemotaxis
Neutrophil-dominant pulmonary inflammation is an important feature of COPD. Since PDE4
inhibitors have a functional role in mediating chemotaxis (Ariga et al., 2004) , the ability of CHF6001 in inhibiting neutrophilic chemotaxis was tested in comparison with roflumilast in vitro in a Boyden two-chamber chemotactic assay. CHF6001 inhibited of about 60% neutrophilic migration with a subnanomolar potency, IC 50 =0.093 nM (0.036-0.241).
Roflumilast, by showing an IC 50 =0.937 nM (0.678-1.296), resulted to be less potent than CHF6001 ( Figure 6 ).
CHF6001 inhibits LPS-induced pulmonary leukocytes infiltration in rat
CHF6001 (CHF, 0.01, 0.1, 0.3, 1 μmoles/kg), GSK256066 (GSK, 1 μmoles/kg) or Budesonide (Bude, 1 μmoles/kg) were administered intra-tracheally as micronized dry powder 1 hour before and 6 hours after LPS challenge. Broncho-alveolar lavage fluid (BALF) was collected 24 hours after challenge and total and differential cell counts performed.
When administered 1 hour before and 6 hours after the inflammatory stimulus, CHF6001 elicited a dose-dependent inhibition of pulmonary neutrophilia which reached a statistical significance at 0.1 μmoles/kg (p<0.05) and was maximal at 1 μmoles/kg (77%) similarly to budesonide at 1 μmoles/kg (77%). CHF6001 elicited also a dose-dependent inhibition of pulmonary white blood cell counts in BALF which reached significance at 0.3 μmoles/kg (p<0.01) and was maximal at 1 μmoles/kg (61%), similarly to budesonide at 1 μmoles/kg (62%). Calculated ED 50 values for This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on January 9, 2015 as DOI: 10.1124/jpet.114.220541
at ASPET Journals on April 8, 2017
jpet.aspetjournals.org
Downloaded from
JPET#220541
22
DISCUSSION
The recent approval of roflumilast as an oral drug for COPD treatment defines the standing of PDE4 as a therapeutic target in respiratory diseases. Nevertheless, this second-generation PDE4
inhibitor is still not without side effects which may compromise optimal dosing and affect patient compliance. Several strategies have been proposed to minimize PDE4 inhibition-related side effects, including designing inhibitors suitable for inhaled delivery that would limit systemic exposure, while increasing the pulmonary anti-inflammatory activity achievable. In the present study we report the pharmacological characterization of a novel highly potent and selective PDE4 inhibitor (CHF6001) optimized for inhaled delivery through a rationale drugdesign and screening program (Armani et al., 2014) . CHF6001 inhibitory potency was evaluated in enzymatic cell free assays and subsequently in several cell-based assays taking advantage of different immuno-competent cells known to play key roles in asthma and COPD, including monocytes, macrophages, CD4+ T cells, neutrophils and eosinophils. Finally, for testing how in vitro anti-inflammatory potency and efficacy translates in vivo, CHF6001 was delivered as micronized dry powder in a rat model of endotoxin-induced acute neutrophilia. A further preclinical in vivo safety and efficacy profile is presented in a companion paper.
CHF6001 was compared with two oral (roflumilast and cilomilast) and two inhaled (GSK256066 and UK500,001) PDE4 inhibitors already described in detail in the scientific literature. Roflumilast was chosen because is the only PDE4 inhibitor approved in EU and USA for once-daily treatment of severe COPD, cilomilast being the first oral PDE4 that reached preregistration and the inhaled PDE4 inhibitors UK 500,001 and GSK256066 because were inhibiting all the four PDE4 (A-D) isoforms tested with a potency comparable to that of GSK256066, which is the most potent inhibitor described in the literature so far, and 10 to 100-fold more potent than roflumilast. Indeed, the following ranking could be determined for inhibition of PDE4 isoforms: GSK256066≥ CHF6001> roflumilast> UK500,001> cilomilast.
Such ranking was substantially maintained when CHF6001 inhibitory PDE4 activity was determined in U937 human monocytic cells lysate.
Two distinct PDE4 conformers can be distinguished based on their affinity to bind the prototypic inhibitor rolipram: the LARBS conformer, encompassing the catalytic domain of PDE4 and the HARBS conformer, which requires both amino terminal and the catalytic domain and present in the brain but not in peripheral tissues (Barnette et al., 1996; Rocque et al., 1997) .
Targeting the conformer of PDE4 associated with the LARBS over the HARBS may retain antiinflammatory activity and have a reduced capacity to cause nausea and emesis (Souness and Rao, 1997) . Interestingly CHF6001 results in a HARBS/LARBS ratio of 40, more than ten-fold higher than roflumilast, UK 500,001 and cilomilast, a characteristic suggestive of a potentially wider therapeutic window.
CHF6001 was tested in several functional cellular assays designed to evaluate its antiinflammatory activities. CHF6001 shows sub-nanomolar potency in inhibiting the release of the clinically relevant pro-inflammatory cytokine TNF-α from PBMCs stimulated with LPS.
Macrophage numbers are markedly increased in the lung and in alveolar space of patients with COPD and are preferentially localized to sites of alveolar destruction. Therefore, alveolar macrophages are critical players in the pathophysiology of COPD and a major target for future anti-inflammatory therapy. Indeed, CHF6001 was also tested in THP-1 monocytic-derived macrophages and two macrophagic cell lines, namely RAW 264.7 which is derived from peritoneal mouse macrophages and NR8383 which is derived from rat alveolar macrophages.
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Again, the anti-inflammatory effects of CHF6001 were evident in all macrophagic cell lines as TNF-α and NO release were inhibited by CHF6001 with potencies slightly inferior (2 to 10 fold potency difference) to those observed in PBMCs. This probably reflects different PDE4 levels of expression between macrophages and monocytes (Gantner et al., 1997) .
CHF6001 was >6000-fold more potent than cilomilast in inhibiting release of IFN-γ in CD4+ T cells which are known to play critical in the initiation and propagation of immune response in asthma (Kumar et al., 2006) . CHF6001 was extremely potent (IC 50 in the low picomolar range)
in inhibiting fMLP-induced eosinophil activation, a finding consistent with the notion that PDE4 is prominently expressed in eosinophils.
Neutrophil-dominant pulmonary inflammation is an important feature of COPD (Watt et al., 2005; Quint and Wedzicha , 2007) and we found that CHF6001 was highly potent in inhibiting fMLP-evoked ROS production from human neutrophils (IC 50 =0.005 nM) and C5a-induced chemotaxis in mouse neutrophils (IC 50 =0.093 nM). Overall, these findings suggest that CHF6001 targets neutrophils both through direct inhibition of oxidative burst and chemotaxis, two biological responses known to be scarcely sensitive to glucocorticoids (Kubo et al., 2012) .
This underlines a therapeutic potential for CHF6001, as well as PDE4 inhibitors, in treating COPD which is often associated with lung neutrophilia.
The high potency of CHF6001 in all the in vitro assays utilized in this study translates well in anti-inflammatory efficacy in vivo when administered intratracheally as a micronized dry powder. By using an endotoxin rat model of pulmonary neutrophilia, we compared CHF6001
head-to-head with the corticosteroid budesonide and GSK256066 (same formulation and same delivery system). GSK256066 was chosen since has been previously reported to be the most potent PDE4 inhibitor so far described in the literature and it is effective in reducing allergen challenge responses in mild asthmatics (Singh et al., 2010) . CHF6001 was highly potent and 
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